173 related articles for article (PubMed ID: 31119966)
21. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
[TBL] [Abstract][Full Text] [Related]
22. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
23. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
24. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
Azzoli CG; Patel JD; Krug LM; Miller V; James L; Kris MG; Ginsberg M; Subzwari S; Tyson L; Dunne M; May J; Huntington M; Saunders M; Sirotnak FM
J Thorac Oncol; 2011 Nov; 6(11):1915-22. PubMed ID: 21841501
[TBL] [Abstract][Full Text] [Related]
25. Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma.
O'Connor OA; Ko BS; Wang MC; Maruyama D; Song Y; Yeoh EM; Manamley N; Tobinai K
Blood Adv; 2024 Jun; 8(11):2601-2611. PubMed ID: 38429077
[TBL] [Abstract][Full Text] [Related]
26. Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial.
Park S; Kim AY; Cho H; Baik D; Lee H; Cho S; Kang HY
BMC Cancer; 2020 Nov; 20(1):1157. PubMed ID: 33243162
[TBL] [Abstract][Full Text] [Related]
27. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
Mould DR; Sweeney K; Duffull SB; Neylon E; Hamlin P; Horwitz S; Sirotnak F; Fleisher M; Saunders ME; O'Connor OA
Clin Pharmacol Ther; 2009 Aug; 86(2):190-6. PubMed ID: 19474785
[TBL] [Abstract][Full Text] [Related]
28. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
Shimanovsky A; Dasanu CA
Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis.
Zhu J; Yeoh EM; Maeda Y; Tobinai K
Leuk Lymphoma; 2020 Sep; 61(9):2145-2152. PubMed ID: 32536233
[TBL] [Abstract][Full Text] [Related]
30. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan.
Ishitsuka K; Yasukawa T; Tsuji Y
Hematol Oncol; 2024 Jul; 42(4):e3292. PubMed ID: 38847317
[TBL] [Abstract][Full Text] [Related]
31. Clinical remission of primary aggressive CD8+ cutaneous T-cell lymphoma after pralatrexate infusion.
Kerdel FA; Styperek AR; Maini A
JAMA Dermatol; 2014 Mar; 150(3):320-2. PubMed ID: 24452280
[No Abstract] [Full Text] [Related]
32. Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin.
Kitazume K; Akagawa Y; Wada S; Suzuki T; Fujita A
Case Rep Oncol; 2019; 12(2):529-536. PubMed ID: 31427947
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
Kawai H; Ando K; Maruyama D; Yamamoto K; Kiyohara E; Terui Y; Fukuhara N; Miyagaki T; Tokura Y; Sakata-Yanagimoto M; Igarashi T; Kuroda J; Fujita J; Uchida T; Ishikawa T; Yonekura K; Kato K; Nakanishi T; Nakai K; Matsunaga R; Tobinai K
Cancer Sci; 2021 Jun; 112(6):2426-2435. PubMed ID: 33792128
[TBL] [Abstract][Full Text] [Related]
34. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
Foss F; Horwitz SM; Coiffier B; Bartlett N; Popplewell L; Pro B; Pinter-Brown LC; Shustov A; Furman RR; Haioun C; Koutsoukos T; O'Connor OA
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):238-43. PubMed ID: 22542448
[TBL] [Abstract][Full Text] [Related]
35. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
36. Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate.
Sekiguchi Y; Wakabayashi M; Takizawa H; Iizuka H; Sakajiri S; Sugimoto K; Inano T; Fukuda Y; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Komatsu N; Noguchi M
J Clin Exp Hematop; 2020; 60(1):26-28. PubMed ID: 32224563
[No Abstract] [Full Text] [Related]
37. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
Bhurani M; Admojo L; Van Der Weyden C; Twigger R; Bazargan A; Quach H; Zimet A; Coyle L; Lindsay J; Radeski D; Hawkes E; Kennedy G; Irving I; Gutta N; Trotman J; Yeung J; Dunlop L; Hua M; Giri P; Yuen S; Panicker S; Moreton S; Khoo L; Scott A; Kipp D; McQuillan A; McCormack C; Dickinson M; Prince HM
Leuk Lymphoma; 2021 Feb; 62(2):330-336. PubMed ID: 33026266
[TBL] [Abstract][Full Text] [Related]
38. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
Marchi E; Raufi AG; O'Connor OA
Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
[TBL] [Abstract][Full Text] [Related]
39. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
Parker T; Barbarotta L; Foss F
Future Oncol; 2013 Jan; 9(1):21-9. PubMed ID: 23252560
[TBL] [Abstract][Full Text] [Related]
40. Small Primary Cutaneous γδT-Cell Lymphoma Lesions Successfully Treated With Pralatrexate.
Imataki O; Uchida S; Yokokura S; Uemura M; Kadowaki N
Clin Nucl Med; 2019 Feb; 44(2):e85-e86. PubMed ID: 30516664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
